Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Transmembrane glycoprotein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Transmembrane glycoprotein NMB is a protein that in humans is encoded by the GPNMB gene. Two transcript variants encoding 560 and 572 amino acid isoforms have been characterized for this gene in humans.
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20130150559A1Strong upregulationImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsAutoimmune conditionDc maturation
Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:NOVO NORDISK AS
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS8231878B2Strong upregulationImmunoglobulin superfamilyPeptide/protein ingredientsDc maturationAutoimmune disease
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:COSMO TECH LTD
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20100310560A1Strong upregulationOrganic active ingredientsImmunoglobulin superfamilyAutoimmune responsesDc maturation
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:COSMO TECH LTD
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS8981061B2Strong upregulationImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsDc maturationApoptosis
Owner:NOVO NORDISK AS
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20090081199A1Strong upregulationOrganic active ingredientsCompound screeningApoptosisAutoimmune disease
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:BIOXELL
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20050260670A1Strong upregulationAntibacterial agentsAntimycoticsAutoimmune diseaseApoptosis
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-beta. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:COLONNA MARCO +1
Trimeric HIV fusion inhibitors for treating or preventing HIV infection
ActiveUS20100204120A1Avoid infectionAvoid fusesPeptide/protein ingredientsAntibody mimetics/scaffoldsImmunodeficiency virusHeptad repeat
Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
Owner:NEW YORK BLOOD CENT
Humanized anti-CD26 antibody and application thereof
ActiveCN103724431APrevent proliferationPrevent invasionFungiBacteriaSingle-Chain AntibodiesComplementarity determining region
The invention provides a novel high-affinity completely humanized antibody which can specifically bind with CD26 as well as a preparation method and application thereof and belongs to the technical field of genetic engineering antibodies. The CD26 is a ubiquitous multifunctional II type transmembrane glycoprotein, has various biological functions and can be interacted with various proteins such as ADA, CD45, FAP-alpha and the like. The invention provides the humanized antibody or a fragment thereof, wherein the antibody or the fragment thereof is capable of specifically binding with the human CD26, preferably the CD26 extracellular domain; the amino acid sequence of the antibody or the fragment thereof comprises an amino acid sequence containing a monoclonal antibody or a fragment thereof or a conjugate of the fragment in any one of 6 complementary determining regions in one of SED ID NO: 2, SED ID NO: 3, SED ID NO: 4, SED ID NO: 6, SED ID NO: 7, and SED ID NO: 8, or an amino acid sequence obtained through amino acid replacement or modification. The obtained anti-CD26 single-chain antibody provided by the invention can highly specifically bind with the CD26 and is simultaneously capable of obviously inhibiting the proliferation, the invasion and the metastasis of tumor cells.
Owner:ZONHON BIOPHARMA INST
Anti-CD26 antibody and application thereof
ActiveCN103641917AGrowth inhibitionPrevent proliferationFungiBacteriaSingle-Chain AntibodiesComplementarity determining region
The invention provides a novel full-humanized antibody which is high in affinity and can be specifically combined with CD26, and a preparation method and application thereof, and belongs to the technical field of a genetically engineered antibody. CD26 is a ubiquitous multifunctional II-type transmembrane glycoprotein, has a plurality of biological functions, and can interact with a plurality of proteins, such as ADA, CD45, FAP-alpha and the like. The invention provides an antibody from a human source or a segment thereof. The antibody or the segment thereof is specifically combined with human CD26, and preferably specifically combined with a CD26 extracellular region; an amino acid sequence of the antibody or the segment thereof comprises a monoclonal antibody which is selected from any region of six complementary determining regions containing a group of sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, or a segment thereof or a conjugate of the segment thereof, or an amino acid sequence which is obtained by amino acid replacement or modification. The anti-CD26 single-chain antibody obtained by the method is highly specifically combined with the CD26, and meanwhile, multiplication of tumor cells can also be obviously inhibited.
Owner:ZONHON BIOPHARMA INST
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20160251434A1Strong upregulationImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsDc maturationApoptosis
Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:NOVO NORDISK AS
Fluorescent probe targeting MUC1 for in-vivo ovarian cancer tissue and preparation method of fluorescent probe
InactiveCN104560026AEnable Specific ImagingSuitable for in vitro detectionFluorescence/phosphorescenceLuminescent compositionsCancer cellWilms' tumor
The invention relates to a fluorescent probe and a preparation method thereof in the technical field of biology, particularly to a fluorescent probe targeting MUC1 of in-vivo ovarian cancer tissue, and the preparation method of the fluorescent probe. The fluorescent probe targeting MUC1 of the in-vivo ovarian cancer tissue consists of an antibody against the MUC1, Cy5.5-n-hydroxy succinimide, and a fluorescein NHS dye. Because the fluorescent probe adopts double marks of the near-infrared fluorescent dye cy5.5 and the fluorescein NHS, which are respectively suitable for in-vivo detection and ex-vivo detection; the MUC1 is I type transmembrane glycoprotein which expresses in various kinds of tissue, organ epithelial cells close to lumens, or glandular cavity surfaces, presents top end secretion and is in extreme distribution, and the expressing quantity of the MUC1 in cancer cells is obviously increased. Researches prove that ovarian cancer cells highly express the MUC1, and therefore, the MUC1 can be used as an ideal target for the treatment of ovarian cancer; the fluorescent probe targeting the MUC1, which is combined with double marks, can completely realize the specificity imaging of the ovarian cancer of a living body, so that real-time tracking in operations is completed.
Owner:THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Human anti-CD26 antibody and applications thereof
ActiveCN103709251AAvoid stickingGrowth inhibitionFungiBacteriaSingle-Chain AntibodiesComplementarity determining region
The invention provides a high-affinity human antibody capable of being combined with the specificity of CD26, and a preparation method and applications thereof, belonging to the technical field of a genetically engineered antibody. CD26 is of a ubiquitously multifunctional II type transmembrane glycoprotein, has multiple biological functions, can act with various proteins such as ADA, CD45, FAP-alpha and the like. The invention provides an antibody or a segment thereof from a human, the antibody or segment thereof specifically combines the human CD26, preferably, specifically combines the CD26 extracellular region, the amino acid sequence of the antibody or the segment thereof comprises an amino acid sequence obtained by performing amino acid replacement or modification to the monoclonal antibody or segments thereof or conjugates of the segments in any one of six complementary decision regions containing a group of sequences: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 AND SEQ ID NO:8. The anti-CD26 single-chain antibody has high specificity combination with the CD26, and the proliferation and invasion and metastasis of tumor cells can be obviously inhibited.
Owner:ZONHON BIOPHARMA INST
Marker for amyotrophic lateral sclerosis, and use thereof
InactiveUS8703433B2Microbiological testing/measurementPeptide preparation methodsAmyotrophic lateral sclerosisBiomarker (petroleum)
An object is to provide a biomarker specific to amyotrophic lateral sclerosis and a use thereof. Provided are a marker for amyotrophic lateral sclerosis containing a transmembrane glycoprotein nmb, and a method for detecting amyotrophic lateral sclerosis, which utilizes the marker, and the like.
Owner:HARA
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20060263770A1Inhibit and reduce spermatogenesisBacteriaPeptide/protein ingredientsDendritic cellAntiendomysial antibodies
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-4 (alpha and beta) and TREM-5 are disclosed. TREM-4 is a transmembrane glycoprotein expressed selectively in the endothelium of capillaries, in the heart and in the testis. Use of TREM-4 in treatment and diagnosis of various inflammatory diseases and heart diseases and male infertility are also provided. TREM-5 is also a transmembrane glycoprotein expressed selectively in bone marrow-derived population of leukocytes, in particular dendritic cells, and may be upregulated in certain conditions, such as cell activation, inflammation or aberrant dendritic cell function. Blockade of TREM-5 with monoclonal antibodies or soluble TREM-5-HuIgG fusion protein may reduce or block skin diseases or dendritic cell associated disorders.
Owner:BIOXELL
Recombinant vector capable of improving solubility of viral glycoprotein, preparation method and applications thereofthereof
ActiveCN108660153AReduced formEfficient preparationSsRNA viruses negative-senseViral antigen ingredientsTransmembrane glycoproteinSolubility
The invention discloses a recombinant vector capable of improving the solubility of viral glycoprotein, and a preparation method thereof, wherein the recombinant vector is formed by co-expressing multi-virus derived M proteins and viral glycoprotein, and comprises a skeleton carrier, a multi-virus derived M protein expression cassette and a viral glycoprotein expression cassette, and the multi-virus derived M protein expression cassette and the viral glycoprotein expression cassette are inserted into the skeleton carrier. According to the present invention, the characteristic that the viral Mprotein can help the transportation of the transmembrane glycoprotein to the cell surface is used so as to prepare the recombinant vector capable of improving the solubility of viral glycoprotein, wherein the expression vector can solve the disadvantages of easy aggregation and difficult dissolution of the viral glycoprotein in the eukaryotic expression cells in the prior art can be solved, and issuitable for the large-scale expression and purification of soluble viral glycoprotein; and with the expression method, the dissolution efficiency of viral glycoprotein is increased, the high immunogenicity of viral glycoprotein is maintained, and the method is suitable for the industrial production and purification of the protein.
Owner:广州源博医药科技有限公司
Prognostic evaluation method for hepatocellular carcinoma through Telocytes
InactiveCN114034722ASolve the problem of the possibility of prognostic evaluation indicatorsPreparing sample for investigationFluorescence/phosphorescenceParanasal Sinus CarcinomaStaining
The invention relates to the technical field of clinical medicine, in particular to a prognostic evaluation method for hepatocellular carcinoma through Telocytes, which comprises the following steps: taking a postoperative tumor specimen of a hepatocellular carcinoma patient, preparing a frozen section or a paraffin section from a cancer cell para-tissue within a range of 1-2cm from the tumor, carrying out immunofluorescent staining by using CD34 (highly glycosylated I-type transmembrane glycoprotein) / CD117 (III-type transmembrane kinase receptor protein) / PDGFR (platelet-derived growth factor receptor) / vimentin (waveform fibrin) indexes, taking CD34 + / CD117 + / PDGFR + / vimentin-cells as TCs cells, putting para-carcinoma tissues into a general stationary liquid for an electron microscope, performing slicing, and observing the morphology of the TCs cells under a transmission electron microscope. According to the prognostic evaluation method for the hepatocellular carcinoma through the Telocytes, multiple groups of double immunofluorescence markers are adopted, and the cell morphology and the telomere number are observed, so that accurate indexes for prognostic evaluation of patients can be provided for clinicians, and the problem of probability of prognostic evaluation indexes of the patients with the hepatocellular carcinoma is solved.
Owner:许莹
Polypeptide-human transmembrane glycopeptide 25 and polynucleotide for encoding such polypeptide
InactiveCN1485340AOrganic active ingredientsPeptide/protein ingredientsImmunologic disordersNucleotide
The present invention provides a polypeptide-human transmembrane glycoprotein 25, polynucleotide for encoding the polypeptide and the process for producing the polypeptide by the DNA restructuring technique. The invention also discloses the method of use of the polypeptide for treating a plurality of diseases, e.g. malignant tumor, hematopathy, HIV affection, immunopathy and various types of inflammation. The invention also discloses the antagonist of the polypeptide and its therapeutic action. The invention also discloses the use of the polynucleotide for coding the new human transmembrane glycoprotein 25. íí
Owner:BIOWINDOW GENE DEV INC
Designing a soluble full-length HIV-1 gp41 trimer
Described herein is a soluble HIV-1 retrovirus transmembrane glycoprotein gp41 trimer (Soc-gp41M-Fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (Soc) protein of bacteriophage T4 and the Foldon domain of the bacteriophage T4 fibritin (Fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of HIV-1 vaccines, diagnostics and therapeutics. Other secondary embodiments of the gp41 proteins containing different modifications are also disclosed. According to one embodiment, the gp41 trimer is further attached to a cell penetration peptide (CPP). Methods of producing gp41 trimers are also disclosed.
Owner:CATHOLIC UNIV OF AMERICA
Application of apelin protein in preparation of reagents for diagnosing respiratory diseases
The invention discloses the application of Apelin protein in preparing reagents for diagnosing respiratory system diseases. The present invention is the first discovery that Apelin-13, especially the combination of Apelin-13, GP73 (Golgi apparatus transmembrane glycoprotein) and Cys-C (cystatin C) can be used as a diagnosis of respiratory diseases, especially the diagnosis of acute lung injury Markers can effectively improve the detection specificity of acute lung injury.
Owner:温州医科大学慈溪生物医药研究院 +1
Coding gene of duck costimulatory molecule CD40 and application of coding gene
InactiveCN110938633APrevent proliferationBacteriaMicroorganism based processesDiseaseProtein molecules
The invention discloses a coding gene of duck costimulatory molecule CD40 and an application of the coding gene, and belongs to the technical field of biology. The nucleotide sequence of the coding gene is shown in SEQ ID No:1, an protein encoded by the gene is composed of 171 amino acid residues, the amino acid sequence is shown in SEQ ID No:2, and the protein molecule forms an extracellular tumor necrosis factor receptor structural domain, a transmembrane structural domain and an intracellular structural domain, and is a 18.8kD I-type transmembrane glycoprotein. The CDS full sequence of theduck costimulatory molecule CD40 provided by the invention has greater practical significance in the development of related detection kits, and the antiviral function has broad application prospects in prevention and treatment of waterfowl diseases.
Owner:SICHUAN AGRI UNIV
Compounds which inhibit HIV replication
InactiveUS20030181382A1Preventing HIV infectionSsRNA viruses negative-senseBiocideImmunodeficiency virusBiochemical Process
This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.
Owner:DUKE UNIV
Marker of neuropathic gaucher's disease and methods of use thereof
InactiveUS20170030926A1Promote effectiveUseful for developmentDisease diagnosisBiological testingDiseaseGPNMB
A biomarker of the neuronopathic types of Gaucher's disease (nGD) is provided, and use thereof for assisting the diagnosis of this form of the disease and its severity. In particular, use of the level of trans-membrane glycoprotein non-metastatic B (GPNMB) or a fragment thereof in the cerebrospinal fluid (CSF) as a diagnostic marker of nGD is provided. Further provided are methods for selecting drugs and assessing the efficacy of drugs and therapies for treating nGD.
Owner:YEDA RES & DEV CO LTD
A magnetic nanoparticle with core-shell structure and its preparation and application
ActiveCN106807308BQuick checkEfficient detectionPreparing sample for investigationMaterial analysis by electric/magnetic meansMagnetite NanoparticlesNanoparti cles
Owner:SHANGHAI JIAOTONG UNIV
Fully human anti-cd26 antibody and its application
ActiveCN103709251BAvoid stickingGrowth inhibitionFungiBacteriaSingle-Chain AntibodiesComplementarity determining region
The invention provides a new high-affinity fully human antibody capable of specifically binding to CD26, a preparation method and application thereof, and belongs to the technical field of genetic engineering antibodies. CD26 is a ubiquitous multifunctional type II transmembrane glycoprotein, which has various biological functions and can interact with various proteins, such as ADA, CD45, FAP-alpha and so on. The present invention provides a human-derived antibody or fragment thereof, which specifically binds to human CD26, preferably specifically binds to the extracellular region of CD26, and the amino acid sequence of the antibody or fragment thereof comprises: SEQ? ID? NO: 2. SEQ? ID? NO: 3. SEQ? ID? NO: 4. SEQ? ID? NO: 6. SEQ? ID? NO: 7, SEQ? ID? NO: 8 A monoclonal antibody or fragment thereof or a conjugate of a fragment thereof in any region of the six complementarity-determining regions of a set of sequences, or an amino acid sequence obtained by amino acid substitution or modification. The anti-CD26 single-chain antibody obtained in the present invention has high specific binding to CD26, and can also obviously inhibit the proliferation, invasion and metastasis of tumor cells.
Owner:ZONHON BIOPHARMA INST
Preparation method of photoelectrochemical sensor for detecting transmembrane glycoprotein CD44 on breast cancer cell surface
PendingCN114878669AMaterial analysis by electric/magnetic meansPhotovoltaic energy generationCD44A-DNA
The invention relates to a preparation method of a photoelectrochemical sensor for detecting transmembrane glycoprotein CD44 on the surface of a breast cancer cell. The preparation method comprises the following three steps: loading a TiO2 nano array on the surface of FTO (Fluorine-doped Tin Oxide) conductive glass by a hydrothermal method, uniformly sputtering an Ag nano layer on the surface of the TiO2 nano array by a magnetron sputtering technology, and finally immersing TiO2-Ag into a sodium sulfide solution to realize local vulcanization of Ag to obtain the photoelectric conversion body TiO2-Ag-Ag2S nano composite array. Then, extracting the transmembrane glycoprotein CD44 on the surface of the breast cancer cell MDA-MB-231 by utilizing the subject-object recognition effect of hyaluronic acid and the transmembrane glycoprotein CD44 and a DNA (Deoxyribose Nucleic Acid) strand displacement reaction; finally, the photoelectric material and a target object are assembled on a conductive interface through biological coupling and covalent bonding, compared with other reported methods, the preparation method of the sensor is high in controllability, and particularly a sensing interface with good signal output stability is obtained. The scheme and process mentioned in the method have important reference in the fields of material synthesis, photoelectrochemical sensing, cell detection and the like.
Owner:UNIV OF JINAN
Application of Apelin protein in preparation of reagent for diagnosing respiratory system diseases
ActiveCN112710847AHigh detection specificityDisease diagnosisBiological testingDiseaseALI - Acute lung injury
The invention discloses an application of Apelin protein in preparation of a reagent for diagnosing respiratory system diseases. What is found for the first time is that the combination of Apelin-13, especially Apelin-13, GP73 (Golgi Transmembrane Glycoprotein) and Cys-C (cystatin C), can be used as a diagnostic marker for diagnosing respiratory system diseases, especially acute lung injury, and the detection specificity of acute lung injury can be effectively improved.
Owner:温州医科大学慈溪生物医药研究院 +1
Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif
ActiveUS9115186B2Avoid infectionAvoid fusesPeptide/protein ingredientsAntipyreticImmunodeficiency virusHeptad repeat
Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
Owner:NEW YORK BLOOD CENT
Marker for amyotrophic lateral sclerosis, and use thereof
InactiveUS20130210033A1Increase credibilityEarly stageMicrobiological testing/measurementDepsipeptidesAmyotrophic lateral sclerosisBiomarker (petroleum)
An object is to provide a biomarker specific to amyotrophic lateral sclerosis and a use thereof. Provided are a marker for amyotrophic lateral sclerosis containing a transmembrane glycoprotein nmb, and a method for detecting amyotrophic lateral sclerosis, which utilizes the marker, and the like.
Owner:HARA
Anti-CD26 antibody and application thereof
ActiveCN103641917BGrowth inhibitionPrevent proliferationFungiBacteriaSingle-Chain AntibodiesComplementarity determining region
The invention provides a novel full-humanized antibody which is high in affinity and can be specifically combined with CD26, and a preparation method and application thereof, and belongs to the technical field of a genetically engineered antibody. CD26 is a ubiquitous multifunctional II-type transmembrane glycoprotein, has a plurality of biological functions, and can interact with a plurality of proteins, such as ADA, CD45, FAP-alpha and the like. The invention provides an antibody from a human source or a segment thereof. The antibody or the segment thereof is specifically combined with human CD26, and preferably specifically combined with a CD26 extracellular region; an amino acid sequence of the antibody or the segment thereof comprises a monoclonal antibody which is selected from any region of six complementary determining regions containing a group of sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, or a segment thereof or a conjugate of the segment thereof, or an amino acid sequence which is obtained by amino acid replacement or modification. The anti-CD26 single-chain antibody obtained by the method is highly specifically combined with the CD26, and meanwhile, multiplication of tumor cells can also be obviously inhibited.
Owner:ZONHON BIOPHARMA INST
Antibodies specific to human nectin-2
The present dislosure provides monoclonal antibodies that recognize human Nectin-2 ( Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com